
China’s Basic Insurance to Cover CAR T-Cell Cancer Therapy
China will include a CAR T-cell therapy in its national health insurance scheme for the first time, making a blood cancer treatment that once cost over 1 million yuan ($150,000) per dose more accessible.
The National Healthcare Security Administration announced on Nov. 14 that relmacabtagene autoleucel, or relma-cel, made by Shanghai-based biotech firm JW Therapeutics and sold under the brand name Carteyva, will be covered by insurance starting Jan. 1. The therapy has three approved uses for different types of lymphoma and costs 1.29 million yuan per dose.
CAR T-cell therapy is primarily used to treat types of lymphoma and involves extracting and genetically modifying a patient’s own immune cells to target cancer cells, before infusing them back into the body. China approved its first CAR T-cell therapy product in 2021.
Most of China’s population is covered by the country’s national insurance scheme: 1.33 billion were enrolled in basic medical insurance by the end of 2025. Only drugs listed in the national insurance catalog can be partially reimbursed through the medical insurance fund. For drugs not listed, patients must usually bear 100% of the cost.
For years, CAR T-cell drugs were excluded from the national insurance list because an unwritten industry rule held that drugs priced above 300,000 yuan rarely secured coverage, limiting patient access, according to Shanghai-based media outlet The Paper.
The rate of CAR T-cell drug use as a second-line treatment for large B-cell lymphoma in China is about one-sixth of that in the United States, while use as a third-line treatment is about one-10th of the rate in the U.S. and Europe.
Carteyva was one of five CAR T-cell therapies included last year in China’s first commercial insurance list for high-cost innovative drugs. This year, those drugs became eligible for national coverage. Two CAR T-cell drug manufacturers, including JW Therapeutics, entered insurance coverage negotiations on Sept. 6.
“Two or three years ago, we wouldn’t have dared to imagine this,” Tian Feng, JW Therapeutics chairman and CEO, told The Paper.
China records about 101,500 new lymphoma cases each year. Carteyva is available at more than 200 certified hospitals nationwide.
The updated national reimbursement list adds 107 drugs covering oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications. A separate commercial insurance list, which covers drugs outside the basic scheme, includes 12 new treatments.
“This is a historic moment for lymphoma patients in China,” Tian said, adding that when he and the company received the news, “everyone really felt that the treatment of lymphoma patients in China had entered a new, very exciting era.”
Editor: Marianne Gunnarsson.
(Header image: VCG)










